These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1070 related items for PubMed ID: 29986185

  • 1. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFRWT and EGFRT790M inhibitors and apoptosis inducers.
    Gaber AA, Bayoumi AH, El-Morsy AM, Sherbiny FF, Mehany ABM, Eissa IH.
    Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
    [Abstract] [Full Text] [Related]

  • 2. Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
    Elmetwally SA, Saied KF, Eissa IH, Elkaeed EB.
    Bioorg Chem; 2019 Jul; 88():102944. PubMed ID: 31051400
    [Abstract] [Full Text] [Related]

  • 3. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
    Sherbiny FF, Bayoumi AH, El-Morsy AM, Sobhy M, Hagras M.
    Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
    [Abstract] [Full Text] [Related]

  • 4. Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M).
    Shaheen MA, El-Emam AA, El-Gohary NS.
    Bioorg Chem; 2020 Dec; 105():104274. PubMed ID: 33339080
    [Abstract] [Full Text] [Related]

  • 5. Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis.
    Maher M, Kassab AE, Zaher AF, Mahmoud Z.
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):532-546. PubMed ID: 30688116
    [Abstract] [Full Text] [Related]

  • 6. Computational and Synthetic approach with Biological Evaluation of Substituted Quinoline derivatives as small molecule L858R/T790M/C797S triple mutant EGFR inhibitors targeting resistance in Non-Small Cell Lung Cancer (NSCLC).
    Karnik KS, Sarkate AP, Tiwari SV, Azad R, Burra PVLS, Wakte PS.
    Bioorg Chem; 2021 Feb; 107():104612. PubMed ID: 33476869
    [Abstract] [Full Text] [Related]

  • 7. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
    Farghaly AM, AboulWafa OM, Baghdadi HH, Abd El Razik HA, Sedra SMY, Shamaa MM.
    Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057
    [Abstract] [Full Text] [Related]

  • 8. Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure-activity relationship and biological activity as potential antitumor and anticonvulsant agents.
    Lamie PF, El-Kalaawy AM, Abdel Latif NS, Rashed LA, Philoppes JN.
    Eur J Med Chem; 2021 Mar 15; 214():113222. PubMed ID: 33545637
    [Abstract] [Full Text] [Related]

  • 9. Design, synthesis and biological evaluation of novel N-(3-amino-4-methoxyphenyl)acrylamide derivatives as selective EGFRL858R/T790M kinase inhibitors.
    Ding S, Dong X, Gao Z, Zheng X, Ji J, Zhang M, Liu F, Wu S, Li M, Song W, Shen J, Duan W, Liu J, Chen Y.
    Bioorg Chem; 2022 Jan 15; 118():105471. PubMed ID: 34798457
    [Abstract] [Full Text] [Related]

  • 10. Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors.
    Zhang B, Liu Z, Xia S, Liu Q, Gou S.
    Eur J Med Chem; 2021 Apr 15; 216():113300. PubMed ID: 33640672
    [Abstract] [Full Text] [Related]

  • 11. Discovery of new pyrimidine-5-carbonitrile derivatives as anticancer agents targeting EGFRWT and EGFRT790M.
    Nasser AA, Eissa IH, Oun MR, El-Zahabi MA, Taghour MS, Belal A, Saleh AM, Mehany ABM, Luesch H, Mostafa AE, Afifi WM, Rocca JR, Mahdy HA.
    Org Biomol Chem; 2020 Oct 07; 18(38):7608-7634. PubMed ID: 32959865
    [Abstract] [Full Text] [Related]

  • 12. Discovery of new 1H-pyrazolo[3,4-d]pyrimidine derivatives as anticancer agents targeting EGFRWT and EGFRT790M.
    Gaber AA, Sobhy M, Turky A, Abdulwahab HG, Al-Karmalawy AA, Elhendawy MA, Radwan MM, Elkaeed EB, Ibrahim IM, Elzahabi HSA, Eissa IH.
    J Enzyme Inhib Med Chem; 2022 Dec 07; 37(1):2283-2303. PubMed ID: 36000168
    [Abstract] [Full Text] [Related]

  • 13. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
    Maher M, Kassab AE, Zaher AF, Mahmoud Z.
    Anticancer Agents Med Chem; 2019 Dec 07; 19(11):1368-1381. PubMed ID: 31038080
    [Abstract] [Full Text] [Related]

  • 14. Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R/T790M/C797S mutant EGFR tyrosine kinase inhibitors.
    Lei H, Fan S, Zhang H, Liu YJ, Hei YY, Zhang JJ, Zheng AQ, Xin M, Zhang SQ.
    Eur J Med Chem; 2020 Jan 15; 186():111888. PubMed ID: 31787359
    [Abstract] [Full Text] [Related]

  • 15. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
    Bakr RB, Mehany ABM, Abdellatif KRA.
    Anticancer Agents Med Chem; 2017 Jan 15; 17(10):1389-1400. PubMed ID: 28270084
    [Abstract] [Full Text] [Related]

  • 16. Discovery of novel pyrrolopyrimidine/pyrazolopyrimidine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors.
    Wang L, Liu X, Duan Y, Li X, Zhao B, Wang C, Xiao Z, Zheng P, Tang Q, Zhu W.
    Chem Biol Drug Des; 2018 Jul 15; 92(1):1301-1314. PubMed ID: 29575727
    [Abstract] [Full Text] [Related]

  • 17. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers.
    Wang C, Xu S, Peng L, Zhang B, Zhang H, Hu Y, Zheng P, Zhu W.
    J Enzyme Inhib Med Chem; 2019 Dec 15; 34(1):203-217. PubMed ID: 30835140
    [Abstract] [Full Text] [Related]

  • 18. New pyrimidine and pyrazole-based compounds as potential EGFR inhibitors: Synthesis, anticancer, antimicrobial evaluation and computational studies.
    Othman IMM, Alamshany ZM, Tashkandi NY, Gad-Elkareem MAM, Anwar MM, Nossier ES.
    Bioorg Chem; 2021 Sep 15; 114():105078. PubMed ID: 34161878
    [Abstract] [Full Text] [Related]

  • 19. Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFRL858R/T790M NSCLCs by the conformation constrained strategy.
    Chen Y, Yang L, Qiao H, Cheng Z, Xie J, Zhou W, Huang X, Jiang Y, Yu B, Zhao W.
    Eur J Med Chem; 2020 Aug 01; 199():112388. PubMed ID: 32402937
    [Abstract] [Full Text] [Related]

  • 20. Synthesis and biological evaluation of irreversible EGFR tyrosine kinase inhibitors containing pyrido[3,4-d]pyrimidine scaffold.
    Zhang H, Wang J, Zhao HY, Yang XY, Lei H, Xin M, Cao YX, Zhang SQ.
    Bioorg Med Chem; 2018 Jul 23; 26(12):3619-3633. PubMed ID: 29853340
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.